Active Ingredient History
Tildrakizumab, sold under the brand names Ilumya and Ilumetri, is a monoclonal antibody designed for the treatment of immunologically mediated inflammatory disorders. It is approved for the treatment of adult patients with moderate-to-severe plaque psoriasis in the United States and the European Union. Wikipedia
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Psoriasis (approved 2018)
Aging (Phase 4)
Arthritis, Psoriatic (Phase 3)
Biological Products (Early Phase 1)
Hematologic Neoplasms (Phase 2)
Hypopigmentation (Early Phase 1)
Pemphigoid, Bullous (Early Phase 1)
Pigmentation Disorders (Early Phase 1)
Prostatic Neoplasms, Castration-Resistant (Phase 1/Phase 2)
Psoriasis (Phase 4)
Skin and Connective Tissue Diseases (Early Phase 1)
Skin Diseases (Early Phase 1)
Spondylitis, Ankylosing (Phase 2)
Vitiligo (Early Phase 1)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
